Key takeaways
Remicade (infliximab) and Humira (adalimumab) are both biologic disease-modifying antirheumatic drug (DMARDs) used to treat various autoimmune conditions, but they have some key differences. Remicade is given through an IV infusion by a healthcare provider, while Humira is a subcutaneous injection that you can administer yourself at home. Remicade is typically given every 6 to 8 weeks, whereas Humira is usually injected every other week. Both medications are available as a brand name, but have several biosimilars available that may make it more affordable. Remicade and Humira can raise the risk of serious infections and certain cancers, but Remicade has a higher risk of causing infusion-related reactions since it is administered intravenously. Additionally, Remicade is not recommended for people with moderate or severe heart failure, while Humira can be used with caution in those with heart conditions.
